The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer
Open accessAbstract
Purpose: RRM1 encodes the regulatory subunit of ribonucleotide reductase and is a molecular target of gemcitabine. Previous studies showed increased RRM1 expression on continuous exposure of cell lines to gemcitabine and suggested improved survival for patients with low as opposed to high tumoral RRM1 expression when treated with gemcitabine-containing chemotherapy. However, the principal hypothesis that intratumoral levels of gene expression are associated with disease response has not been addressed. Patients and Methods: We constructed genetically modified lung cancer cell lines with increased and decreased RRM1 expression to investigate the in vitro 50% inhibitory concentration (IC 50) for gemcitabine, cisplatin, and carboplatin. A prospective phase II clinical trial in patients with locally advanced non–small-cell lung cancer was conducted with pretreatment tumor collection for determination of RRM1 and ERCC1 expression by real-time reverse transcriptase polymerase chain reaction. The levels of gene expression were correlated with tumor response after two cycles of gemcitabine and carboplatin. Results: In cell lines with a genetically engineered 15-fold RRM1 expression range, the gemcitabine IC 50 had a 100-fold range, and the cisplatin and carboplatin IC 50 had a two-fold range. They were highest in constructs with high RRM1 expression. In the prospective clinical trial, RRM1 expression was significantly (P = .002) and inversely correlated (r = −0.498) with disease response. ERCC1 expression showed a similar trend (P = .099). Conclusion: The results strongly suggest that tumoral RRM1 expression is a major predictor of disease response to gemcitabine/platinum chemotherapy. ERCC1 expression is predictive of response albeit to a lesser degree.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,181
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M.-S., Sakurada, A., Cutz, J.-C., Zhu, C.-Q., Kamel-Reid, S., Squire, J., Lorimer, I., Zhang, T., Liu, N., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,830
Fossella, F. V., DeVore, R., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L., Miller, V., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Kelly, K., Crowley, J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,123
Fossella, F., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczęsna, A., Fidias, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.046 · Cited by 939
(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett, W. K., Huang, P., Xu, Y.-Z., Heinemann, V., Grunewald, R., & Gandhi, V. V. (1995) · PubMed · Cited by 753
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
From RNA to DNA, Why So Many Ribonucleotide Reductases?
Reichard, P. (1993) · Science · doi:10.1126/science.8511586 · Cited by 530
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
Bergman, A. M., Pinedo, H. M., & Peters, G. J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00002-x · Cited by 360
Rosell, R., Danenberg, K. D., Alberola, V., Bepler, G., Sanchez, J. J., Camps, C., Provencio, M., Isla, D., Taron, M., Diz, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0156 · Cited by 352
Self-citationSmit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Ribonucleotide reductase: regulation, regulation, regulation
Elledge, S. J., Zhou, Z., & Allen, J. B. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90249-9 · Cited by 309
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H. N., Pirker, R., Berthet, P., Breau, J. L., Lianes, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299
Davidson, J. D., Ma, L., Flagella, M., Geeganage, S., Gelbert, L. M., & Slapak, C. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3363 · Cited by 280
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005) · Chest · doi:10.1378/chest.127.3.978 · Cited by 277
Self-citationKosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.112 · Cited by 255
Gridelli, C., Gallo, C., Shepherd, F. A., Illiano, A., Piantedosi, F., Robbiati, S. F., Manzione, L., Barbera, S., Frontini, L., Veltri, E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.099 · Cited by 247
Bergman, A. M., Eijk, P. P., Ruiz van Haperen, V. W. T., Smid, K., Veerman, G., Hubeek, I., van den IJssel, P., Ylstra, B., & Peters, G. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0989 · Cited by 182
Bepler, G., Sharma, S., Cantor, A., Gautam, A., Haura, E., Simon, G., Sharma, A., Sommers, E., & Robinson, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.002 · Cited by 179
Self-citationEquilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Rauchwerger, D. R., Firby, P., Hedley, D. W., & Moore, M. J. (2000) · PubMed · Cited by 150
RRM1-induced metastasis suppression through PTEN-regulated pathways
Gautam, A., Li, Z.-R., & Bepler, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206232 · Cited by 146
Self-citationRibonucleotide reductases in the twenty-first century
Stubbe, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2723 · Cited by 96
Eliopoulos, N., Cournoyer, D., & Momparler, R. L. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050832 · Cited by 94
Gemcitabine in the treatment of non-small-cell lung cancer
Burkes, R. L. (1996) · Lung Cancer · doi:10.1016/0169-5002(96)87867-6 · Cited by 34
Mouse ribonucleotide reductase: from genes to proteins
Filatov, D. E., Ingemarson, R., Johansson, E., Rova, U., & Thelander, L. (1995) · Biochemical Society Transactions · doi:10.1042/bst0230903 · Cited by 12
Cited by
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Lung cancer: Biology and treatment options
Lemjabbar-Alaoui, H., Hassan, O. U., Yang, Y.-W., & Buchanan, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,014
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Self-citationGelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., & Bepler, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065411 · Cited by 462
Self-citation
Metadata
- Authors
- Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-10-10
- Volume
- 24
- Issue
- 29
- Pages
- 4731-4737
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105202429
- Cited by
- 333
- References
- 32
- FWCI
- 25.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.